Table 1 Baseline characteristics for the total group.

From: Serum levels of anti-Müllerian hormone influence pregnancy outcomes associated with gonadotropin-releasing hormone antagonist treatment: a retrospective cohort study

 

Group A (AMH = 1.1–4.0 ng/ml)

Group B (AMH > 4.0 ng/ml)

p value

Number

639

740

 

Age(years)

34.24 ± 4.21

31.67 ± 4.08

 < 0.001

BMI(kg/m2)

22.83 ± 4.46

23.28 ± 7.86

0.205

Duration of infertility(years)

3.80 ± 3.02

3.40 ± 2.66

0.009

PCOS (%)

24(3.76%)

175(23.65%)

 < 0.001

Basal FSH(IU/ml)

7.81 ± 2.45

6.70 ± 1.91

 < 0.001

Basal LH(IU/ml)

4.02 ± 1.96

5.07 ± 2.87

 < 0.001

AMH(ng/ml)

2.29 ± 0.80

7.10 ± 3.88

 < 0.001

AFC(n)

9.23 ± 4.28

15.93 ± 6.83

 < 0.001

Initial Gn dose(IU)

261.69 ± 79.62

187.92 ± 57.27

 < 0.001

Gn Duration(-days)

9.28 ± 1.65

9.48 ± 1.68

0.029

Total Gn dose (IU)

2654.14 ± 908.48

1896.41 ± 689.52

 < 0.001

Endometrial thickness(cm)

0.98 ± 0.26

0.98 ± 0.33

0.871

E2 on HCG day(ng/ml)

1981.56 ± 1289.64

2999.74 ± 1525.09

 < 0.001

LH on HCG day(mIU/ml)

3.43 ± 3.67

3.12 ± 2.98

 < 0.001

P on HCG day(ng/ml)

1.21 ± 1.30

1.40 ± 1.37

0.009